Viral replication inhibitors

A method of inhibiting Dengue virus or yellow fever virus replication, by the administration of an effective amount of a compound of formula B:

• or a pharmaceutically acceptable salt thereof, optionally in combination with one or more other medicines, to a human patient in need thereof,
• wherein
• the moiety
• is
• wherein the wavy line ()
• indicates the point of attachment to the carbonyl of the main formula (B);
• wherein said moiety is substituted with one or more Z1;
• cycle B is
• wherein the wavy line () indicates the point of attachment to the carbon atom of the main formula (B), and wherein the depicted cycles are substituted with one, two, or three Z1a;
• R1 is phenyl;
• wherein said phenyl is substituted with one, two, or three Z1b;
• R2 is hydrogen;
• each Z1 and Z1a is independently selected from the group consisting of halogen, hydroxyl, —OZ2, —O—C(═O)Z3, ═O, —S(═O)2Z3, —S(═O)2NZ4Z5, trifluoromethyl, trifluoromethoxy, —NZ4Z5, —NZ4C(═O)Z2, —NZ4C(═O)OZ2, cyano, —C(═O)Z3, —C(═O)OZ2, —C(═O)NZ4Z5, C1-6alkyl, heteroC1-6alkyl, aryl, heterocycle, and heterocycle-C1-6alkyl;
• and wherein said C1-6alkyl, heteroC1-6alkyl, aryl, heterocycle, and heterocycle-C1-6alkyl, are optionally substituted with one, two, or three substituents selected from hydroxyl, ═O, halogen, trifluoromethyl, —OCF3, —O—C(O)Me, cyano, nitro, —C(O)OH, —C(O)OC1-6alkyl, —NH2, —NHCH3;
• —N(CH3)2, —NH—C(═O)O—C1-4alkyl, —S(O)2C1-4alkyl, and —O—C1-6alkyl;
• each Z1b is independently selected from the group consisting of hydroxyl, —OZ2, —O—C(═O)Z3, ═O, —S(═O)2Z3, —S(═O)2NZ4Z5, trifluoromethyl, trifluoromethoxy, —NZ4Z5, —NZ4C(═O)Z2, —NZ4C(═O)OZ2, cyano, —C(═O)Z3, —C(═O)OZ2, —C(═O)NZ4Z5, C3-6alkyl, heteroC1-6alkyl, aryl, heterocycle, and heterocycle-C1-6alkyl;
• and wherein said C3-6alkyl, heteroC1-6alkyl, aryl, heterocycle, and heterocycle-C1-6alkyl, are optionally substituted with one, two, or three substituents selected from hydroxyl, ═O, halogen, trifluoromethyl, —OCF3, —O—C(O)Me, cyano, nitro, —C(O)OH, —C(O)OC1-6alkyl, —NH2, —NHCH3;
• —N(CH3)2, —NH—C(═O)O—C1-4alkyl, —S(O)2C1-4alkyl, and —O—C1-6alkyl;
• each Z2 is independently selected from C1-6alkyl, aryl, heterocycle, and heterocycle-C1-6alkyl;
• wherein said C1-6alkyl, aryl, heterocycle, and heterocycle-C1-6alkyl, are optionally substituted with one, two, or three substituents selected from hydroxyl, ═O, halogen, trifluoromethyl, difluoromethyl, —O—C1-6alkyl, —OCF3, —S(═O)2C1-4alkyl, cyano, —C(═O)OH, —C(═O)O—C1-4alkyl, —NH2, —N(CH3)2, pyrrolidinyl, piperidinyl, and piperazinyl, wherein said C1-6alkyl is not substituted with hydroxyl;
• each Z3 is independently selected from hydroxyl, aryl, and heterocycle;
• wherein said and heterocycle are optionally substituted with one, two, or three substituents selected from C1-6alkyl and —N(CH3)2;
• each Z4 and Z5 is independently selected from hydrogen, C1-6alkyl, aryl, C3-7cycloalkyl, and heterocycle;
• or an isomer thereof, or a solvate thereof, or a salt thereof, or a prodrug thereof;
• wherein the term “heterocycle” means a saturated, unsaturated, or aromatic ring system of 3 to 18 atoms including at least one N, O, S, or P.